BLACK DIAMOND THERAPEUTICS I (BDTX) Stock News

NASDAQ:BDTX - US09203E1055 - Common Stock

2.94 USD

+0.07 (+2.44%)

Last: 9/5/2025, 8:00:01 PM

2.94 USD

0 (0%)

After Hours: 9/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BDTX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Zacks Investment Research - Mentions: AZN JNJ

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

2 days ago - By: Zacks Investment Research - Mentions: AZN JNJ

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

18 days ago - By: Zacks Investment Research

Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why

19 days ago - By: Zacks Investment Research - Mentions: BRTX

Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?

a month ago - By: The Motley Fool

Black Diamond (BDTX) Q2 Loss Narrows 47%

a month ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Yahoo Finance - Mentions: RJF

Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise

3 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

4 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

6 months ago - By: Benzinga - Mentions: CANF TNXP HQY INTS ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

6 months ago - By: Benzinga

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million

6 months ago - By: Black Diamond Therapeutics, Inc

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

6 months ago - By: Black Diamond Therapeutics, Inc

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

6 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

6 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024